6 terminated, 3 completed, 1 withdrawn. 6 Phase 1, 3 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 3, Completed 2, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow milademetan: new trials by email Literature Review of milademetan trials Research Report on milademetan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL) - Advanced or Metastatic Breast Cancer | Phase 2 | Terminated | Institut Curie | 1 | 2023-10-12 | 2023-12-21 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects Placebo, Moxifloxacin (positive control), Milademetan - Cardiac Repolarization | Phase 1 | Terminated | Rain Oncology Inc | 6 | 2023-04-17 | 2023-08-08 |
| Milademetan in Advanced/Metastatic Solid Tumors RAIN-32 - Solid Tumors, Head and Neck Carcinoma | Phase 2 | Terminated | Rain Oncology Inc | 40 | 2021-11-01 | 2024-10-17 |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma RAIN-32, Trabectedin - Dedifferentiated Liposarcoma | Phase 3 | Terminated | Rain Oncology Inc | 175 | 2021-07-14 | 2025-01-14 |
| Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Quizartinib, Milademetan - Acute Myeloid Leukemia | Phase 1 | Terminated | Daiichi Sankyo | 10 | 2018-12-12 | 2022-05-20 |
| Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Milademetan - Acute Myeloid Leukemia | Phase 1 | Completed | Daiichi Sankyo Co., Ltd. | 14 | 2018-08-23 | 2023-11-07 |
| Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants Milademetan, Itraconazole, Posaconazole - Pharmacokinetics | Early Phase 1 | Completed | Daiichi Sankyo | 36 | 2018-07-13 | 2019-02-12 |
| Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Milademetan, AZA - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 | Terminated | Daiichi Sankyo | 74 | 2014-11-25 | 2021-10-11 |
| A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas Milademetan - Advanced Solid Tumor, Lymphoma | Phase 1 | Completed | Daiichi Sankyo | 107 | 2013-07-11 | 2025-03-27 |
Leukemia, Myeloid, Acute (3) · Melanoma (2) · Recurrence (2) · Sarcoma (2) · Stomach Neoplasms (2) · Adenocarcinoma of Lung (1) · Adrenocortical Carcinoma (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Liposarcoma (1) · Lymphoma (1) · Mesothelioma (1)
Daiichi Sankyo (4) · Rain Oncology Inc (4) · Daiichi Sankyo Co., Ltd. (1) · Institut Curie (1)
United States (6) · France (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Georgia (1) · Germany (1) · Hong Kong (1) · Ireland (1) · Italy (1) · Japan (1) · Poland (1) · South Korea (1) · Spain (1)